Lixa Pty Ltd
Lixa is a biotech company dedicated to resolving recurring microbial infections and contaminations by addressing the global challenge of antimicrobial resistance (AMR). The company is pioneering a technology platform called NeoX™, which aims to restore the effectiveness of existing antimicrobials and biocides against resistant bacteria. Lixa's mission is to develop scalable, cost-effective solutions that can be applied across various sectors, including human, animal, plant, marine, and industrial applications, to combat AMR and improve global health.
What We Do
NeoX™ is a technology platform developed by Lixa to restore the effectiveness of existing antimicrobials and biocides against resistant bacteria. It includes a proprietary, non-antibiotic, small molecule that causes rapid collapse of mature biofilms and sensitizes bacteria to accessible, affordable existing therapies. NeoX-101, the lead development candidate, is in preparation to enter clinical development in 2024 as an inhaled therapy for respiratory infections.
Services
Drugs
Key People
CEO, Managing Director
Chair
Director
Director
CFO
News & Updates
A new training Centre led by The University of Queensland is partnering with industry to tackle the global crisis of antimicrobial-resistant infections, which affect humans, animals and the environment.
Lixa has received Human Research Ethics Committee (HREC) approval to commence its first human trial - a Phase I clinical trial assessing the safety and tolerability of NeoX™ in an inhaled formulation.
Lixa has received an Innovation Booster grant from the Department of Jobs, Tourism, Science and Innovation and the WA Government's New Industries Fund.
Lixa is on a mission to resolve recurring microbial infections and contaminations by developing a novel approach that makes resistant bacteria vulnerable to antibiotics and the immune system again.
Mila – Quebec AI Institute and Lixa have announced a partnership to combine Lixa’s antibiofilm knowledge with Mila’s expertise in artificial intelligence to combat antimicrobial resistance.
Lixa was announced as the winner of the WA Innovator of the Year 2022 Wesfarmers Wellbeing Platinum award.